This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for leptomeningeal metastases.
This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of tomotherapy for leptomeningeal metastases, which are defined as leptomeningeal metastases with or without brain metatstases.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
103
1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases; 2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles. d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF).
Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
overall survival
the time from radiation to death
Time frame: up to 2 years
local control
the time from radiation to leptomeningeal lesion recurrence
Time frame: up to 1 year
intracranial progress free survival
the time from radiation to leptomeningeal lesion recurrence and/or new brain metastases
Time frame: up to 1 year
progress free survival rate
the time from radiation to any progression
Time frame: up to 1 year
adverse event
acute and late toxicities
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.